Two New Drugs Approved for Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Metastatic non-small cell lung cancer (NSCLC) presents treatment challenges.
• Targeted therapies are advancing NSCLC treatment.
• Genetic mutations like MET exon 14 skipping and HER2 mutations are key targets.

Purpose of the Study:

• To report FDA approvals for new NSCLC treatments.
• To highlight capmatinib for MET exon 14 skipping mutations.
• To inform about Enhertu for HER2-mutated NSCLC.

Main Methods:

• Review of FDA approvals and associated clinical data.
• Identification of specific genetic alterations targeted by new therapies.
• Summary of key adverse events and warnings.

Main Results:

• Capmatinib (Tabrecta) approved for metastatic NSCLC with MET exon 14 skipping.
• Fam-trastuzumab deruxtecan-nxki (Enhertu) approved for previously treated, HER2-mutated metastatic NSCLC.
• Serious adverse events for capmatinib include interstitial lung disease and hepatotoxicity.
• Enhertu carries a boxed warning for interstitial lung disease and embryo-fetal toxicity.

Conclusions:

• New targeted therapies offer treatment options for specific NSCLC patient populations.
• Vigilant patient monitoring for adverse effects is crucial for safe and effective treatment.
• FDA approvals signify advancements in personalized medicine for NSCLC.